Dexcom Appoints Renée Galá to Board of Directors
DexCom (NASDAQ:DXCM), the global leader in glucose biosensing, has appointed Renée Galá to its Board of Directors, effective March 6, 2025. Galá currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals, a global biopharmaceutical company with over $4 billion in 2024 revenues.
In her role at Jazz Pharmaceuticals, Galá oversees global business operations including commercial operations, research and development, manufacturing, corporate strategy and quality. She brings significant financial, strategic, and operational leadership experience across the life sciences sector, including expertise in international expansion initiatives and business development collaborations.
DexCom (NASDAQ:DXCM), leader globale nel biosensing della glucosio, ha nominato Renée Galá nel suo Consiglio di Amministrazione, con effetto dal 6 marzo 2025. Galá attualmente ricopre il ruolo di Presidente e Direttore Operativo di Jazz Pharmaceuticals, un'azienda biofarmaceutica globale con oltre 4 miliardi di dollari di fatturato nel 2024.
Nel suo ruolo presso Jazz Pharmaceuticals, Galá supervisiona le operazioni commerciali globali, comprese le operazioni commerciali, la ricerca e sviluppo, la produzione, la strategia aziendale e la qualità. Porta con sé una significativa esperienza in leadership finanziaria, strategica e operativa nel settore delle scienze della vita, inclusa l'expertise in iniziative di espansione internazionale e collaborazioni per lo sviluppo commerciale.
DexCom (NASDAQ:DXCM), líder mundial en biosensores de glucosa, ha nombrado a Renée Galá en su Junta Directiva, con efecto a partir del 6 de marzo de 2025. Galá actualmente se desempeña como Presidenta y Directora de Operaciones de Jazz Pharmaceuticals, una compañía biofarmacéutica global con más de 4 mil millones de dólares en ingresos en 2024.
En su papel en Jazz Pharmaceuticals, Galá supervisa las operaciones comerciales globales, incluidas las operaciones comerciales, la investigación y el desarrollo, la fabricación, la estrategia corporativa y la calidad. Aporta una experiencia significativa en liderazgo financiero, estratégico y operativo en el sector de las ciencias de la vida, incluida la experiencia en iniciativas de expansión internacional y colaboraciones en desarrollo empresarial.
DexCom (NASDAQ:DXCM), 포도당 바이오센싱 분야의 글로벌 리더,는 Renée Galá를 이사회에 임명하였으며, 이는 2025년 3월 6일부터 효력이 발생합니다. Galá는 현재 2024년 수익이 40억 달러를 초과하는 글로벌 생명공학 회사 Jazz Pharmaceuticals의 사장 겸 최고 운영 책임자로 재직하고 있습니다.
Jazz Pharmaceuticals에서의 역할로, Galá는 상업 운영, 연구 및 개발, 제조, 기업 전략 및 품질을 포함한 글로벌 비즈니스 운영을 감독합니다. 그녀는 생명 과학 분야에서 재무, 전략 및 운영 리더십 경험을 쌓았으며, 국제 확장 이니셔티브 및 비즈니스 개발 협력에 대한 전문성을 보유하고 있습니다.
DexCom (NASDAQ:DXCM), leader mondial dans le domaine des biosenseurs de glucose, a nommé Renée Galá au sein de son conseil d'administration, à compter du 6 mars 2025. Galá occupe actuellement le poste de Présidente et Directrice des opérations de Jazz Pharmaceuticals, une entreprise biopharmaceutique mondiale affichant plus de 4 milliards de dollars de revenus en 2024.
Dans son rôle chez Jazz Pharmaceuticals, Galá supervise les opérations commerciales mondiales, y compris les opérations commerciales, la recherche et le développement, la production, la stratégie d'entreprise et la qualité. Elle apporte une expérience significative en leadership financier, stratégique et opérationnel dans le secteur des sciences de la vie, y compris une expertise dans les initiatives d'expansion internationale et les collaborations en développement commercial.
DexCom (NASDAQ:DXCM), der globale Marktführer im Bereich der Glukose-Biosensorik, hat Renée Galá mit Wirkung zum 6. März 2025 in seinen Vorstand berufen. Galá ist derzeit Präsidentin und Chief Operating Officer von Jazz Pharmaceuticals, einem globalen biopharmazeutischen Unternehmen mit über 4 Milliarden Dollar Umsatz im Jahr 2024.
In ihrer Rolle bei Jazz Pharmaceuticals überwacht Galá die globalen Geschäftsabläufe, einschließlich der kommerziellen Abläufe, Forschung und Entwicklung, Produktion, Unternehmensstrategie und Qualität. Sie bringt umfassende Erfahrung in finanzieller, strategischer und operativer Führung im Bereich der Lebenswissenschaften mit, einschließlich Fachwissen in internationalen Expansionsinitiativen und Geschäftsentwicklungspartnerschaften.
- Addition of experienced executive with global operations expertise
- Strategic appointment bringing international expansion experience
- New board member from $4B+ revenue company adding valuable perspective
- None.
Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than
“We are excited to announce Renée’s appointment to the Dexcom Board today and benefit from her insights,” said Kevin Sayer, chairman, president and CEO at Dexcom. “Dexcom has a unique opportunity ahead of us to empower greater metabolic health for millions of people around the world. Renée’s extensive experience guiding global finance and global operations including commercial and R&D to drive growth and create shareholder value provides an excellent fit at this key point in Dexcom’s journey.”
About Renée Galá
Renée Galá has served as the President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, since 2023. From 2020 to 2023, Ms. Galá served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals. From January to June 2019, Ms. Galá served as the Chief Financial Officer of GRAIL, Inc., a private healthcare company focused on the early detection of cancer. Prior to that, from December 2014 to January 2019, she served as Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc., a biopharmaceutical company, following its spin-out from Theravance, Inc. (now INVA). Ms. Galá joined Theravance in 2006 and held various roles in the finance organization before leading the company’s spin-out transaction.
Prior to that, Ms. Galá served in various roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company, a global pharmaceutical company, from 2001 to 2006. Before joining Eli Lilly, Ms. Galá spent seven years in the energy industry in positions focused on corporate finance, project finance, and mergers and acquisitions.
Ms. Galá has served as a non-executive director for multiple companies in the biotech/life sciences industry, including Gossamer Bio, Gyroscope Therapeutics (acquired by Novartis), and Corcept Therapeutics. Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.
About DexCom, Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
Category: IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310902935/en/
Media Contact
James McIntosh
619-884-2118
mediarelations@dexcom.com
Investor Contact
Sean Christensen
858-203-6657
investor-relations@dexcom.com
Source: DexCom, Inc.
FAQ
When will Renée Galá join DexCom's Board of Directors?
What is Renée Galá's current position before joining DXCM's board?
What experience does Renée Galá bring to DXCM's board?
What are Renée Galá's responsibilities at Jazz Pharmaceuticals?
